If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 1994 B.S., School of Pharmacy, Taipei Medical University
  • 1996 M.S., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
  • 2000 Ph.D., Graduate Institute of Pharmaceutical Sciences, National Taiwan University

Experience

Professional Experiences:

  • 2013- Jointly Appointed Professor, Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University
  • 2013- Jointly Appointed Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
  • 2012- Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
  • 2008-2012 Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
  • 2004-2008 Assistant Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
  • 2000-2004 Postdoctoral Research, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes

Administrative experiences:

  • 2018- Dean, College of Pharmacy, Taipei Medical University
  • 2017- Director, Biomedical Commercialization Center, Taipei Medical University
  • 2015- Director, Research Center of Pharmaceutical Sciences and Biotechnology, College of Pharmacy, Taipei Medical University
  • 2013-2017 Associate Dean, College of Pharmacy, Taipei Medical University
  • 2012-2016 Director, Core Laboratory of Drug Organic Synthesis, Taipei Medical University

Awards

1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion

Research Interests

  1. Discovery and Development of small molecular compounds towards IND
  2. Structure optimization through rational drug design and intelligent modification
  3. Medicinal Chemistry

Fingerprint Dive into the research topics where Jing-Ping Liou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Histone Deacetylase Inhibitors Medicine & Life Sciences
Tubulin Medicine & Life Sciences
Tubulin Modulators Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Histone Deacetylases Medicine & Life Sciences
Inhibitory Concentration 50 Medicine & Life Sciences
Antimitotic Agents Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2021

有機金屬催化反應於合成化學和藥物化學之抗癌表觀遺傳學抑制劑研究(1/2)

Liou, J.

8/1/197/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

研究計畫補助費-延攬博士後獎勵補助(劉景平)

Liou, J.

2/1/191/31/21

Project: A - Government Institutionf - Other (Funded by Government)

研究計畫補助費-延攬博士後獎勵補助(劉景平)

Liou, J.

9/21/189/20/20

Project: A - Government Institutionf - Other (Funded by Government)

發展抗肺纖維化劑-合成抗肺纖維化合物

Liou, J.

1/1/1912/1/19

Project: A - Government Institutiond - Ministry of Education

亞太生醫矽谷精準醫療旗艦計畫-臺北醫學大學合作案

Liou, J.

1/1/1912/1/19

Project: A - Government Institutiona - National Health Research Institutes

Research Output 1996 2019

  • 2707 Citations
  • 28 h-Index
  • 118 Article
  • 3 Review article
5 Citations (Scopus)

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase

Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., Jan 15 2019, In : European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.

Research output: Contribution to journalArticle

Benzamides
Histone Deacetylases
Tubulin
Heterografts
Inhibitory Concentration 50
Growth Inhibitors
Amides
Prostatic Neoplasms
Cells
Lead compounds
3 Citations (Scopus)

Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo

Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation
1 Citation (Scopus)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Chao, M. W., Chang, L. H., Tu, H. J., Chang, C. D., Lai, M. J., Chen, Y. Y., Liou, J. P., Teng, C. M. & Pan, S. L., May 29 2019, In : Clinical Epigenetics. 11, 1, 85.

Research output: Contribution to journalArticle

Open Access
Histone Deacetylase Inhibitors
Mitogen-Activated Protein Kinase Kinases
Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Heterografts
1 Citation (Scopus)

MPT0G413, A novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells

Huang, F. I., Wu, Y. W., Sung, T. Y., Liou, J. P., Lin, M. H., Pan, S. L. & Yang, C. R., Jan 1 2019, In : Frontiers in Oncology. 9, APR, 249.

Research output: Contribution to journalArticle

Open Access
Histone Deacetylases
Multiple Myeloma
Neoplasms
Histone Deacetylase Inhibitors
Growth